IBX Investor Webcast Presentation
Released
Released
Announcement PDF
Investor Webcast
MagSense First-in-Human Study
10:30am AEST, 23 June 2020
www.imagionbiosystems.com
Study Overview
Staging of HER2 metastatic
breast cancer by the detection
of tumor cells in lymph nodes
Phase I Study
Multi-Site in AUS
Timing
• Primary endpoint
is testing for
patient safety
• 3-5 clinical sites in
Australia (VIC and
NSW)
• Enrolment
expected to
commence in Q4
• 2nd endpoint is an
initial assessment
of effectiveness
• Goal of testing 1520 subjects up to a
maximum 40
• Study duration of
6-9 months
depending on
subject availability
and number of
sites
Advantages of an Australian Study
Favorable regulatory and clinical research
environment reduces risk of delays
Ability to add MRI with Siemens Healthcare
collaboration
Leverages support of local KOLs
Eligibility for ATO R&D tax credit
Data usable in future dealings with FDA
COVID-19 risk mitigation
Brings our business closer to our Australian
investors
Multi-modal study will provide an
indication of MagSense targeted
nanoparticles for use with
magnetic relaxometry and MRI
IMAGIONBIOSYSTEMS.COM | 3
Pathway to Study Initiation
CRO Appointed
Human Research Ethics Committee (HREC) Submission
and Approval
Completion of Manufacturing of the
MagSense™ nanoparticles
Clinical sites and Principal Investigators
contracted
Targeting Subject Enrolment Q4 2020
IMAGIONBIOSYSTEMS.COM | 4
Transformative for Medical Imaging
The MagSense™ HER2 Metastatic Breast Cancer Test
•
Works within current standard cancer diagnosis and staging
protocols.
•
Replaces current non-functional imaging such as MRI or
ultrasound used to assess for enlarged lymph nodes but which
cannot determine if tumor cells are present.
•
Would eliminate unnecessary biopsies for patients that do not
have metastatic spread to the lymph nodes.
•
Would reduce incidence of lymphedema and associated
morbidity.
The MagSense™ system and test has been designated by the FDA as a
Breakthrough Device - reserved for products that provide for more effective
treatment or diagnosis.
IMAGIONBIOSYSTEMS.COM | 5
Q&A
Please raise your hand in Zoom or
leave a question in the Q&A section,
and the IBX team will respond in turn.
IMAGIONBIOSYSTEMS.COM | 6
Contact:
www.imagionbiosystems.com
info@imagionbio.com
ASX: IBX
Share your feedback
Discover